Healthcare | May 19, 2026
Zydus Wellness FY26 revenue climbs to Rs. 39.4 billion
Growth driven by strong performance across Sugar Free, RiteBite Max Protein, Everyuth, Glucon-D and Nutralite portfolios
Growth driven by strong performance across Sugar Free, RiteBite Max Protein, Everyuth, Glucon-D and Nutralite portfolios
The drug also delivered a disease control rate (DCR) of 83.3% in high-dose cohorts and a mean progression-free survival of 6.3 months in SCLC patients
This positions its platform as a rapidly evolving engine for next-generation genetic medicine
US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya
Company enters women’s personal grooming segment while strengthening pain management portfolio with herbal Ortho Oil
30,000 sq. ft. multispeciality facility aims to deliver integrated care for women across every life stage
New facility ‘Amber Wing’ adds 55 beds and strengthens surgical, cardiac, robotic and preventive care infrastructure for women in Mumbai
The 38% adjusted EBITDA margin of base business has been supported by robust growth in the CDMO segment
Medanta expanded its bed capacity by 20% during the year
The product is bioequivalent and therapeutically equivalent to the reference listed drug by Fresenius Kabi USA, LLC.
Subscribe To Our Newsletter & Stay Updated
